

Canadian Sentinel Practitioner Surveillance Network (SPSN) influenza vaccine effectiveness estimates % (95% CI), 2004-05 to 2016-17 seasons

Season (number of participants)	Influenza Type/Subtype				
	Any Influenza Type/Subtype	Type A	A/H1N1	A/H3N2	Type B
2004-05 ¹ (131)	40 (-75, 80)	-	-	-	-
2005-06 ² (442)	61 (26, 79)	70 (29, 87)	-	70 (29, 87)	48 (-21, 77)
2006-07 ³ (841)	46 (17, 65)	49 (20, 68)	92 (34, 99)	41 (6, 63)	12 (-134, 67)
2007-08 ⁴ (1425)	60 (45, 71)	64 (47, 75)	69 (44, 83)	57 (32, 73)	55 (32, 70)
2008-09 ⁵ (1529)	56 (41, 67)	59 (42, 71)	68 (45, 81)	55 (33, 70)	56 (31, 72)
2009-10 ⁶ (552)	93 (69, 98)	93 (69, 98)	93 (69, 98)	-	-
2010-11 ⁷ (1718)	37 (17, 52)	43 (21, 59)	59 (14, 80)	39 (14, 57)	25 (-18, 52)
2011-12 ⁸ (1507)	59 (43, 70)	69 (48, 81)	80 (52, 92)	51 (10, 73)	51 (26, 67)
2012-13 ⁹ (1501)	50 (33, 63)	45 (24, 60)	59 (16, 80)	41 (17, 59)	68 (44, 82)
2013-14 ¹⁰ (1700)	68 (58, 76)	66 (52, 76)	71 (58, 80)	-	72 (55, 82)
2014-15 ¹¹ (1929)	9 (-14, 27)	-13 (-45, 12)	-	-17 (-50, 9)	45 (18, 64)
2015-16 ¹² (2007)	46 (32, 57)	44 (27, 57)	43 (25, 57)	-	50 (31, 63)
2016-17 ^{13e} (2074)	45 (31, 56)	37 (20, 51)	-	37 (20, 51)	73 (52, 84)

References:

- Skowronski DM et al. *Can Commun Dis Rep*. 2005;31:181-91: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05vol31/dr3118-eng.php
- Skowronski DM et al. *Vaccine*. 2007;25(15):2842-51: www.sciencedirect.com/science/article/pii/S0264410X06011054
- Skowronski DM et al. *J Infect Dis*. 2009;199:168-79: jid.oxfordjournals.org/content/199/2/168.full
- Janjua NZ et al. *J Infect Dis*. 2012;205:1858-68: jid.oxfordjournals.org/content/205/12/1858.long
- Skowronski DM et al. *PLoS Med*. 2010;7(4):e1000258: www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000258
- Skowronski DM et al. *British Medical Journal*. 2011;342:c7297. Doi:10.1136/bmj.c7297: www.bmj.com/content/342/bmj.c7297?view=long&pmid=21292718
- Skowronski DM et al. *Clinical Infect Dis*. 2012;55:332-42: cid.oxfordjournals.org/content/55/3/332.long
- Skowronski DM et al. *J Infect Dis*. 2014; 210:126-37: jid.oxfordjournals.org/content/210/1/126.long
- Skowronski DM et al. *PLOS ONE*. 2014;9(3):e92153: www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0092153
 - For mid-season estimate, see: Skowronski DM et al. *Euro Surveill*. 2013;18(5):pii=20394: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20394
- Skowronski DM et al. *J Infect Dis*. 2015;212(5):726-39: academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiv177
 - For mid-season estimate, see: Skowronski DM et al. *Euro Surveill*. 2014;19(5):pii=20690: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20690
- Skowronski DM et al. *Clinical Infect Dis*. 2016;63(1):21-32: cid.oxfordjournals.org/content/63/1/21.long
 - For mid-season estimate, see: Skowronski DM et al. *Euro Surveill*. 2015 Jan 29;20(4): pii 21022: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21022
- Skowronski DM et al. *J Infect Dis*. 2017 [Epub ahead of print]: <https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jix526/4356858>
 - For mid-season estimate, see: Chambers C et al. *Euro Surveill*. 2016 ;21(11):pii=30168: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21415
- Skowronski DM et al. *I-MOVE Annual Meeting* May 2017 [manuscript in preparation]
 - For mid-season estimate, see: Skowronski DM et al. *Euro Surveill*. 2017;22(6):pii=30460: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22714